Everest Organics Ltd

icon 4.55 | 3.68
Market Cap ₹( Cr.)
Proj. P/E (x)
Proj. P/BV (x)
Proj. ROE (%)
Proj EV / EBITDA (x)
Proj. Revenue ( Cr.)

Stock View

Last Updated On.

The average score for Everest Organics Ltd stands at 2 against 2, three months back.

Everest Organics Limited is an India-based company, which is engaged in manufacturing of active pharmaceutical ingredients (API) and their intermediaries. It is involved in manufacturing of bulk drugs, such as Omeprazole, Ciprofloxacin, Dichloroflurobenzene, Naproxen, Benzimadizole. The Company’s API’s products include Pantoprazole Sodium Sesquihydrate USP/BP/EP/IP, Esomeprazole Magnesium Trihydrate-USP/BP/IP/EP, Esomeprazole Magnesium Trihydrate-USP/BP, Esomeprazole Magnesium Dihydrate, Omeprazole Powder-USP / BP/ EP/IP, Omeprazole Magnesium-IP/EP/USP and others. Its intermediates products include 2-Mercapto-5-Methoxy Benzimidazole (Omeprazole-Benzimidazole), 2-Chloro-Methyl-3,5-Dimethyl-4-Methoxy Pyridine HCL (Omeprazole Chloro Compound), Ammonium Sulphate, Sodium Nitrite and others. Its products under development include Sitagliptin, Vildagliptin, Ilaprazole, N-(5-Amino-2-Methylphenyl)-4-(3-Pyridyl)-2-Pyrimidineamine (Imatinib Intermediate), Lanso Sulphide and others.

Disclaimer : All estimates (1 year forward) are based on Consensus View provided by Refinitiv.

Technical Data

50 DMA(₹)
100 DMA(₹)
200 DMA(₹)
52 Weeks Range
95.00     152.70

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required